{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:05:10Z","timestamp":1790147110184,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Key Research and Development Program of heilongjiang","award":["2023ZX06C09"],"award-info":[{"award-number":["2023ZX06C09"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62372141"],"award-info":[{"award-number":["62372141"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Super-enhancers are clusters of cis-regulatory elements that sustain the expression of cell-identity genes. Their aberrant activation or dysfunction constitutes a hallmark of malignant cellular transformation, which frequently rewires oncogenic transcriptional programs to support uncontrolled cell proliferation and metastatic potential. However, the functions and epigenetic regulation mechanisms of colorectal cancer specific super-enhancers remain poorly understood, and few studies have focused on dissecting how tumor enriched super-enhancers mediate downstream oncogenic signaling in CRC. By integrating multi-omics sequencing data, we identified a highly active super-enhancer in colorectal cancer, termed DCBLD2-SE. Through luciferase reporter assays, the SE3-2 subregion was identified as the minimal functional core of this super-enhancer. Mechanistic studies confirmed that transcription factors of the activator protein-1 family (FOSL2 and JUND) can bind directly to the SE3-2 cis-regulatory element, synergistically regulating local chromatin remodeling and strongly driving the upregulation of the target gene\n                    <jats:italic>DCBLD2<\/jats:italic>\n                    . Following knockout of the DCBLD2-SE core region, the malignant proliferative capacity of colorectal cancer cells decreased significantly, and the growth of xenograft tumors in vivo was markedly inhibited. Functionally, DCBLD2-SE facilitates tumor progression through a DCBLD2-dependent CD146\/AKT\/TNFRSF6B signaling axis. Clinically, high expression of\n                    <jats:italic>DCBLD2<\/jats:italic>\n                    correlates with malignant metastasis and poor overall survival in patients with colorectal cancer. In summary, this study uncovers a previously undescribed DCBLD2-centered regulatory cascade that promotes colorectal cancer initiation and progression. DCBLD2-SE and its binding transcription factor activator protein-1 represent promising prognostic biomarkers and actionable therapeutic targets for colorectal cancer.\n                  <\/jats:p>","DOI":"10.1186\/s43556-026-00592-4","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:56:09Z","timestamp":1790146569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The DCBLD2 super-enhancer drives colorectal cancer progression through FOSL2\/JUND-mediated activation of the CD146\/AKT\/TNFRSF6B pathway"],"prefix":"10.1186","volume":"7","author":[{"given":"Tong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boshu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijia","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"3","key":"592_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"592_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-024-04692-x","volume":"39","author":"F Shakeri","year":"2024","unstructured":"Shakeri F, Mohamadynejad P, Moghanibashi M. Identification of ASMTL-AS1 and LINC02604 lncRNAs as novel biomarkers for diagnosis of colorectal cancer. Int J Colorectal Dis. 2024;39(1):112. https:\/\/doi.org\/10.1007\/s00384-024-04692-x.","journal-title":"Int J Colorectal Dis"},{"issue":"5","key":"592_CR3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41575-022-00736-1","volume":"20","author":"H Bando","year":"2023","unstructured":"Bando H, Ohtsu A, Yoshino T. Therapeutic landscape and future direction of metastatic colorectal cancer. Nat Rev Gastroenterol Hepatol. 2023;20(5):306\u201322. https:\/\/doi.org\/10.1038\/s41575-022-00736-1.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"592_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2025.100831","volume":"6","author":"S Li","year":"2025","unstructured":"Li S, Zhao W, An Q, Wang L, Zhu M, Ni J, et al. Novel cancer stem cell-targeted retinoid ZSH-512 impedes colorectal cancer progress via KDM3A-mediated epigenetic reprogramming. Innovation. 2025;6(4):100831. https:\/\/doi.org\/10.1016\/j.xinn.2025.100831.","journal-title":"Innovation"},{"key":"592_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.artmed.2025.103180","volume":"167","author":"Z Yao","year":"2025","unstructured":"Yao Z, Fang K, Liu G, Bj\u00f8r\u00e5s M, Jin VX, Wang J. Integrated analysis of differential intra-chromosomal community interactions: a study of breast cancer. Artif Intell Med. 2025;167:103180. https:\/\/doi.org\/10.1016\/j.artmed.2025.103180.","journal-title":"Artif Intell Med"},{"issue":"1","key":"592_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03599-5","volume":"25","author":"X Lu","year":"2025","unstructured":"Lu X, Zhu M, Pei X, Ma J, Wang R, Wang Y, et al. Super-enhancers in hepatocellular carcinoma: regulatory mechanism and therapeutic targets. Cancer Cell Int. 2025;25(1):7. https:\/\/doi.org\/10.1186\/s12935-024-03599-5.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"592_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13072-023-00502-w","volume":"16","author":"RW Zhou","year":"2023","unstructured":"Zhou RW, Parsons RE. Etiology of super-enhancer reprogramming and activation in cancer. Epigenetics Chromatin. 2023;16(1):29. https:\/\/doi.org\/10.1186\/s13072-023-00502-w.","journal-title":"Epigenetics Chromatin"},{"issue":"2","key":"592_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10555-023-10103-4","volume":"42","author":"M Bacabac","year":"2023","unstructured":"Bacabac M, Xu W. Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets. Cancer Metastasis Rev. 2023;42(2):471\u201380. https:\/\/doi.org\/10.1007\/s10555-023-10103-4.","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"592_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102146","volume":"6","author":"T Xia","year":"2025","unstructured":"Xia T, Yin H, Zhu Q, Zhang K, Xie H, Shan Y, et al. DDX5 super-enhancer promotes vasculogenic mimicry formation and metastasis in nasopharyngeal carcinoma by enhancing ADAM10 transcription. Cell Rep Med. 2025;6(6):102146. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102146.","journal-title":"Cell Rep Med"},{"issue":"8","key":"592_CR10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI177599","volume":"135","author":"SQ Liu","year":"2025","unstructured":"Liu SQ, Cheng XX, He S, Xia T, Li YQ, Peng W, et al. Super-enhancer-driven EFNA1 fuels tumor progression in cervical cancer via the FOSL2-Src\/AKT\/STAT3 axis. J Clin Invest. 2025;135(8):e177599. https:\/\/doi.org\/10.1172\/JCI177599.","journal-title":"J Clin Invest"},{"issue":"1","key":"592_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01775-6","volume":"9","author":"H Qian","year":"2023","unstructured":"Qian H, Zhu M, Tan X, Zhang Y, Liu X, Yang L. Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets. Cell Death Discov. 2023;9(1):470. https:\/\/doi.org\/10.1038\/s41420-023-01775-6.","journal-title":"Cell Death Discov"},{"issue":"1","key":"592_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-025-03596-5","volume":"26","author":"S Gregoricchio","year":"2025","unstructured":"Gregoricchio S, Kojic A, Hoogstraat M, Schuurman K, Stelloo S, Severson TM, et al. Endometrial tumorigenesis involves epigenetic plasticity demarcating non-coding somatic mutations and 3D-genome alterations. Genome Biol. 2025;26(1):124. https:\/\/doi.org\/10.1186\/s13059-025-03596-5.","journal-title":"Genome Biol"},{"key":"592_CR13","doi-asserted-by":"publisher","unstructured":"Voutsadakis IA. Targeting super-enhancer activity for colorectal cancer therapy. Am J Transl Res. 2024;16(3):700\u2013719. https:\/\/doi.org\/10.62347\/QKHB5897.","DOI":"10.62347\/QKHB5897"},{"issue":"1","key":"592_CR14","doi-asserted-by":"publisher","first-page":"12861","DOI":"10.1038\/s41598-021-92026-0","volume":"11","author":"KM Alhamoudi","year":"2021","unstructured":"Alhamoudi KM, Barhoumi T, Al-Eidi H, Asiri A, Nashabat M, Alaamery M, et al. A homozygous nonsense mutation in DCBLD2 is a candidate cause of developmental delay, dysmorphic features and restrictive cardiomyopathy. Sci Rep. 2021;11(1):12861. https:\/\/doi.org\/10.1038\/s41598-021-92026-0.","journal-title":"Sci Rep"},{"key":"592_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.669285","volume":"9","author":"P Xie","year":"2021","unstructured":"Xie P, Yuan FQ, Huang MS, Zhang W, Zhou HH, Li X, et al. DCBLD2 affects the development of colorectal cancer via EMT and angiogenesis and modulates 5-FU drug resistance. Front Cell Dev Biol. 2021;9:669285. https:\/\/doi.org\/10.3389\/fcell.2021.669285.","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"592_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.1223","volume":"12","author":"S Min","year":"2024","unstructured":"Min S, Zhang L, Zhang L, Liu F, Liu M. LncRNA MIR100HG affects the proliferation and metastasis of lung cancer cells through mediating the microRNA-5590-3p\/DCBLD2 axis. Immun Inflamm Dis. 2024;12(4):e1223. https:\/\/doi.org\/10.1002\/iid3.1223.","journal-title":"Immun Inflamm Dis"},{"key":"592_CR17","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.18816","volume":"13","author":"Z Wang","year":"2025","unstructured":"Wang Z, Li S, Zheng F, Xiong S, Zhang L, Wan L, et al. Construction and validation of prognosis and treatment outcome models based on plasma membrane tension characteristics in bladder cancer. PeerJ. 2025;13:e18816. https:\/\/doi.org\/10.7717\/peerj.18816.","journal-title":"PeerJ"},{"issue":"1","key":"592_CR18","doi-asserted-by":"publisher","DOI":"10.1049\/syb2.70043","volume":"19","author":"L Wan","year":"2025","unstructured":"Wan L, Li J, Xie X. A super-enhancer-related ferroptosis signature predicts survival and immune microenvironment in colon cancer based on bioinformatics analyses and experimental validation. IET Syst Biol. 2025;19(1):e70043. https:\/\/doi.org\/10.1049\/syb2.70043.","journal-title":"IET Syst Biol"},{"issue":"1","key":"592_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","volume":"150","author":"MA Dawson","year":"2012","unstructured":"Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12\u201327. https:\/\/doi.org\/10.1016\/j.cell.2012.06.013.","journal-title":"Cell"},{"issue":"1","key":"592_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41698-025-01003-7","volume":"9","author":"HE Marei","year":"2025","unstructured":"Marei HE. Epigenetic regulators in cancer therapy and progression. NPJ Precis Oncol. 2025;9(1):206. https:\/\/doi.org\/10.1038\/s41698-025-01003-7.","journal-title":"NPJ Precis Oncol"},{"issue":"3","key":"592_CR21","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nm.2305","volume":"17","author":"M Rodr\u00edguez-Paredes","year":"2011","unstructured":"Rodr\u00edguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011;17(3):330\u20139. https:\/\/doi.org\/10.1038\/nm.2305.","journal-title":"Nat Med"},{"issue":"1","key":"592_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12964-016-0161-y","volume":"15","author":"C Roschger","year":"2017","unstructured":"Roschger C, Cabrele C. The Id-protein family in developmental and cancer-associated pathways. Cell Commun Signal. 2017;15(1):7. https:\/\/doi.org\/10.1186\/s12964-016-0161-y.","journal-title":"Cell Commun Signal"},{"issue":"2","key":"592_CR23","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.molcel.2015.02.014","volume":"58","author":"D Hnisz","year":"2015","unstructured":"Hnisz D, Schuijers J, Lin CY, Weintraub AS, Abraham BJ, Lee TI, et al. Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. Mol Cell. 2015;58(2):362\u201370. https:\/\/doi.org\/10.1016\/j.molcel.2015.02.014.","journal-title":"Mol Cell"},{"issue":"5","key":"592_CR24","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.cell.2014.10.024","volume":"159","author":"E Chipumuro","year":"2014","unstructured":"Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014;159(5):1126\u201339. https:\/\/doi.org\/10.1016\/j.cell.2014.10.024.","journal-title":"Cell"},{"issue":"9","key":"592_CR25","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/ncb3216","volume":"17","author":"F Zanconato","year":"2015","unstructured":"Zanconato F, Forcato M, Battilana G, Azzolin L, Quaranta E, Bodega B, et al. Genome-wide association between YAP\/TAZ\/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol. 2015;17(9):1218\u201327. https:\/\/doi.org\/10.1038\/ncb3216.","journal-title":"Nat Cell Biol"},{"issue":"4","key":"592_CR26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1101\/gr.267898.120","volume":"31","author":"J Seo","year":"2021","unstructured":"Seo J, Ko\u00e7ak DD, Bartelt LC, Williams CA, Barrera A, Gersbach CA, et al. AP-1 subunits converge promiscuously at enhancers to potentiate transcription. Genome Res. 2021;31(4):538\u201350. https:\/\/doi.org\/10.1101\/gr.267898.120.","journal-title":"Genome Res"},{"key":"592_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1224892","volume":"14","author":"D Song","year":"2023","unstructured":"Song D, Lian Y, Zhang L. The potential of activator protein 1 (AP-1) in cancer targeted therapy. Front Immunol. 2023;14:1224892. https:\/\/doi.org\/10.3389\/fimmu.2023.1224892.","journal-title":"Front Immunol"},{"issue":"1","key":"592_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3892\/ijmm.2019.4390","volume":"45","author":"G Zhu","year":"2020","unstructured":"Zhu G, Cheng Z, Huang Y, Zheng W, Yang S, Lin C, et al. MyD88 mediates colorectal cancer cell proliferation, migration and invasion via NF\u2011\u03baB\/AP\u20111 signaling pathway. Int J Mol Med. 2020;45(1):131\u201340. https:\/\/doi.org\/10.3892\/ijmm.2019.4390.","journal-title":"Int J Mol Med"},{"issue":"17","key":"592_CR29","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019103209","volume":"39","author":"N Feldker","year":"2020","unstructured":"Feldker N, Ferrazzi F, Schuhwerk H, Widholz SA, Guenther K, Frisch I, et al. Genome-wide cooperation of EMT transcription factor ZEB1 with YAP and AP-1 in breast cancer. EMBO J. 2020;39(17):e103209. https:\/\/doi.org\/10.15252\/embj.2019103209.","journal-title":"EMBO J"},{"issue":"13","key":"592_CR30","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1038\/s41388-021-01724-6","volume":"40","author":"M Riedel","year":"2021","unstructured":"Riedel M, Berthelsen MF, Cai H, Haldrup J, Borre M, Paludan SR, et al. In vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit Jun. Oncogene. 2021;40(13):2437\u201347. https:\/\/doi.org\/10.1038\/s41388-021-01724-6.","journal-title":"Oncogene"},{"issue":"3","key":"592_CR31","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.devcel.2022.01.007","volume":"57","author":"J Kim","year":"2022","unstructured":"Kim J, Minna JD. AP-1 leads the way in lung cancer transformation. Dev Cell. 2022;57(3):292\u20134. https:\/\/doi.org\/10.1016\/j.devcel.2022.01.007.","journal-title":"Dev Cell"},{"issue":"4","key":"592_CR32","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/cr.2009.34","volume":"19","author":"J Du","year":"2009","unstructured":"Du J, Yang S, An D, Hu F, Yuan W, Zhai C, et al. BMP-6 inhibits microRNA-21 expression in breast cancer through repressing deltaEF1 and AP-1. Cell Res. 2009;19(4):487\u201396. https:\/\/doi.org\/10.1038\/cr.2009.34.","journal-title":"Cell Res"},{"issue":"5","key":"592_CR33","doi-asserted-by":"publisher","first-page":"E131","DOI":"10.1038\/ncb0502-e131","volume":"4","author":"E Shaulian","year":"2002","unstructured":"Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002;4(5):E131\u20136. https:\/\/doi.org\/10.1038\/ncb0502-e131.","journal-title":"Nat Cell Biol"},{"key":"592_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117225","volume":"178","author":"F Li","year":"2024","unstructured":"Li F, Tian J, Zhang L, He H, Song D. A multi-omics approach to reveal critical mechanisms of activator protein 1 (AP-1). Biomed Pharmacother. 2024;178:117225. https:\/\/doi.org\/10.1016\/j.biopha.2024.117225.","journal-title":"Biomed Pharmacother"},{"key":"592_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950831","volume":"13","author":"P Xie","year":"2022","unstructured":"Xie P, Liu JY, Yan H, Wang ZB, Jiang SL, Li X, et al. Pan-cancer analyses identify DCBLD2 as an oncogenic, immunological, and prognostic biomarker. Front Pharmacol. 2022;13:950831. https:\/\/doi.org\/10.3389\/fphar.2022.950831.","journal-title":"Front Pharmacol"},{"issue":"2","key":"592_CR36","doi-asserted-by":"publisher","first-page":"560","DOI":"10.7150\/jca.90059","volume":"15","author":"T Li","year":"2024","unstructured":"Li T, Lei Z, Wei L, Yang K, Shen J, Hu L. Tumor necrosis factor receptor-associated factor 6 and human cancer: a systematic review of mechanistic insights, functional roles, and therapeutic potential. J Cancer. 2024;15(2):560\u201376. https:\/\/doi.org\/10.7150\/jca.90059.","journal-title":"J Cancer"},{"key":"592_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102203","volume":"51","author":"Y Huang","year":"2025","unstructured":"Huang Y, Jin J, Ren N, Chen H, Qiao Y, Zou S, et al. ZNF37A downregulation promotes TNFRSF6B expression and leads to therapeutic resistance to concurrent chemoradiotherapy in rectal cancer patients. Transl Oncol. 2025;51:102203. https:\/\/doi.org\/10.1016\/j.tranon.2024.102203.","journal-title":"Transl Oncol"},{"issue":"3","key":"592_CR38","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1021\/np100736y","volume":"74","author":"KP Devkota","year":"2011","unstructured":"Devkota KP, Ratnayake R, Colburn NH, Wilson JA, Henrich CJ, McMahon JB, et al. Inhibitors of the oncogenic transcription factor AP-1 from Podocarpus latifolius. J Nat Prod. 2011;74(3):374\u20137. https:\/\/doi.org\/10.1021\/np100736y.","journal-title":"J Nat Prod"},{"issue":"8","key":"592_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06915-z","volume":"15","author":"L Shao","year":"2024","unstructured":"Shao L, Yu H, Wang M, Chen L, Ji B, Wu T, et al. DKK1-SE recruits AP1 to activate the target gene DKK1 thereby promoting pancreatic cancer progression. Cell Death Dis. 2024;15(8):566. https:\/\/doi.org\/10.1038\/s41419-024-06915-z.","journal-title":"Cell Death Dis"},{"issue":"3","key":"592_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03538-6","volume":"12","author":"S Cui","year":"2021","unstructured":"Cui S, Wu Q, Liu M, Su M, Liu S, Shao L, et al. EphA2 super-enhancer promotes tumor progression by recruiting FOSL2 and TCF7L2 to activate the target gene EphA2. Cell Death Dis. 2021;12(3):264. https:\/\/doi.org\/10.1038\/s41419-021-03538-6.","journal-title":"Cell Death Dis"},{"issue":"2","key":"592_CR41","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in The Cancer Genome Atlas. Cell. 2018;173(2):321-337.e10. https:\/\/doi.org\/10.1016\/j.cell.2018.03.035.","journal-title":"Cell"},{"issue":"2","key":"592_CR42","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Lov\u00e9n","year":"2013","unstructured":"Lov\u00e9n J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153(2):320\u201334. https:\/\/doi.org\/10.1016\/j.cell.2013.03.036.","journal-title":"Cell"},{"key":"592_CR43","doi-asserted-by":"publisher","unstructured":"To KKW, Xing E, Larue RC, Li P-KJM. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications. Molecules. 2023;28(7):3043. https:\/\/doi.org\/10.3390\/molecules28073043.","DOI":"10.3390\/molecules28073043"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00592-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00592-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00592-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:56:10Z","timestamp":1790146570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00592-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["592"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00592-4","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"15 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal experiments were performed in strict accordance with the Guide for the Care and Use of Laboratory Animals from Harbin Institute of Technology (HIT). All animal procedures were approved by HIT Institutional Animal Care and Use Committee (approval number: IACUC-2026034). This study did not employ human patient tissue samples or individual human subject data; human participant consent: Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"183"}}